Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.
He has an MA from University of Sioux Falls. You can connect with Jared on LinkedIn.
MM Progression, Treatment Do Not Appear to Impact COVID-19 Mortality, Study Finds
July 4th 2020A new study that looked at a cohort of 58 patients with multiple myeloma (MM) who contracted COVID-19 found the disease itself does not appear to be linked with higher mortality when these individuals are hospitalized.
Read More
CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain
July 2nd 2020There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to meaningful advances in the therapy of multiple myeloma. However, investigators will first need to clear a number of key hurdles.
Read More
Defining Transitional MS Remains a Tricky, but Important, Problem
July 2nd 2020Most patients who have multiple sclerosis (MS) begin with a relapsing-remitting phase and eventually transition to a secondary progressive phase. In between is believed to be a “transitional” phase, but scientists have yet to discover how to clearly identify patients in transition.
Read More
COVID-19 Raises Difficult Challenges for CAR T-Cell Therapy Administration
June 27th 2020Patients with B-cell non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia can benefit greatly from chimeric antigen receptor (CAR) T-cell therapy, but providing that therapy has become much more difficult in the age of coronavirus disease 2019 (COVID-19).
Read More
Young Adults With Cancer More Likely to Have Germline Mutations, Study Finds
June 27th 2020Patients between the ages of 18 and 39 who are diagnosed with solid-tumor cancers are more likely than the general population to have germline mutations that could make them more susceptible to secondary primary cancers, according to new research.
Read More
MRD Should Be More Widely Used in Clinical Care of MM, Report Argues
June 26th 2020Minimal residual disease (MRD) status has been shown to be a better indicator of the prognosis of a patient with multiple myeloma (MM) than “complete remission.” Yet, it’s still not widely used in the clinic. A new article examines the problem.
Read More
Rituximab, Anthracycline Have Benefits in Oldest Patients With Diffuse Large B-Cell Lymphoma
June 20th 2020Most studies of patients with diffuse large B-cell lymphoma do not include those over the age of 80. However, a new study says those patients, like younger patients, benefit from receiving rituximab and anthracycline in their chemotherapy regimens when possible.
Read More
Newly Identified MicroRNA Signatures Could Reshape Pediatric ALL Diagnosis, Study Says
June 19th 2020Diagnosis pediatric acute lymphoblastic leukemia (ALL) can be a costly and cumbersome experience. New research has identified microRNA signatures that could simplify the process of diagnosis and classifying the cancer.
Read More
New Method Enables Smartphone-Based Diagnosis of Sickle Cell Disease
June 14th 2020Patients with sickle cell disease who do not receive treatment can die from the disease, but diagnostic resources are scarce in some parts of the world where the disease is most prevalent. A new smartphone-based method could change that.
Read More
CAG Regimen Shows Strong Results as Salvage Therapy in T-ALL
June 13th 2020Patients with relapsed/refractory T-cell lymphoblastic leukemia face poor outcomes, and are generally treated by salvage therapy followed by allogeneic hematopoietic stem cell transplant. A new study suggests an optimal option for salvage therapy.
Read More
Review Finds Questions Remaining About Ibrutinib Dose Modification in CLL
June 13th 2020A subset of patients taking ibrutinib as a therapy for chronic lymphocytic leukemia (CLL) will require dose modifications. A new study attempts to evaluate the impacts of such changes, though the authors find many questions remain unsolved.
Read More
Induction Therapy Optimal for Transplant-Eligible Patients With Multiple Myeloma
June 11th 2020A new large randomized trial indicates induction therapy including lenalidomide is optimal in patients with multiple myeloma who are transplant-eligible. Maintenance with lenalidomide was preferable to observation alone following transplant.
Read More
New Tool Aims for Accurate Risk Assessment in AML, Even With Gaps in Data
June 6th 2020Accurate risk assessment is a highly technical process for patients with acute myeloid leukemia (AML). A new tool could help make such assessments available even when patients can’t get to a specialty care center.
Read More
Prolonged Lenalidomide Maintenance Deepens Disease Response in MM
June 6th 2020A new study finds a significant proportion of patients with multiple myeloma (MM) who receive lenalidomide maintenance will see their disease response deepen and many will achieve minimal residual disease negativity.
Read More
Biomarker Advances Bring New Hope of Targeted PTCL Therapy
June 6th 2020Peripheral T-cell lymphoma (PTCL) has been a challenging nemesis for scientists, in large part because it is a widely heterogeneous disease. However, new research into biomarkers for the cancer may lead to better therapies soon.
Read More
Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care
June 2nd 2020As investigators have learned more about how to diagnose and categorize smoldering multiple myeloma (SMM), a new review article argues there’s insufficient data to evolve beyond a close observation approach.
Read More
Gap Remains in Identifying Patients With Psoriasis Likely to Develop Psoriatic Arthritis
May 29th 2020Despite some clues, scientists don’t yet understand which patients with psoriasis are likely to eventually develop psoriatic arthritis; solving that riddle could have major impacts on patient care.
Read More
Dimethyl Fumarate Safe, Effective Against Relapsing-Remitting MS in New Long-term Results
May 28th 2020A new study that looks at the long-term effects of dimethyl fumarate finds the therapy is safe and effective in patients with relapsing-remitting multiple sclerosis who have taken the therapy for approximately a decade.
Read More